In August 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …

Purpose Low-molecular weight heparin (LMWH) followed by vitamin K antagonists (VKAs)
are the current standard treatment of acute venous thromboembolism (VTE) and prevention …

Introduction: Randomized controlled trials that compared direct oral anticoagulants (DOACs)
to vitamin K antagonists (VKA) for the treatment of venous thromboembolism (VTE) …

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) have been included in
international guidelines as important alternatives to vitamin K antagonists (VKAs) for the …

Objectives In the 'Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight
Heparin in Patients With Cancer With Venous Thromboembolism'(SELECT-D) trial …

Objectives: To assess the comparative budget and health impact of lower-dose dabigatran
versus reduced doses of apixaban and rivaroxaban in atrial fibrillation (AF) patients eligible …

Background Dutch guidelines advise extended anticoagulant treatment with direct oral
anticoagulants or vitamin K antagonists for patients with idiopathic venous …

Introduction Venous thromboembolism (VTE) prophylaxis guidelines for non-surgical
patients recommend VTE-and bleeding risk assessment to guide prophylactic strategies …

PREVENTION AND MANAGEMENT OF VENOUS THROMBOEMBOLISM Page 1
PREVENTION AND MANAGEMENT OF VENOUS THROMBOEMBOLISM INTERNATIONAL …

Objective: The last standard treatment for venous thromboembolism (VTE) is oral
anticoagulation with a vitamin K antagonist. Treatment with a vitamin K antagonist requires …